Phase 4 Completed N=64 Randomized Single-blind Treatment

Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis

Cirrhosis · Portal Vein Thrombosis

Source: ClinicalTrials.gov NCT04173429 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2021

Primary outcomePrimary: Recanalization Rate — 20; 11 Participants

◆ Published Evidence

No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

The study is aimed at evaluating the efficacy and safety of anticoagulant therapy with nadroparin calcium and warfarin in patients with portal vein thrombosis (PVT).

Outcome Measures

Outcome	Result	p-value
PRIMARY Recanalization Rate	20; 11	—
SECONDARY Rate of Bleeding	1; 0	—

Eligibility Criteria

Inclusion Criteria

Age between 18 and 75 years
Liver cirrhosis diagnosis based on clinical, laboratory, and imaging studies, and PVT diagnosed by abdominal contrast-enhanced computed tomography, contrast-enhanced MRI, or portal angiography

Exclusion Criteria

Cavernous transformation of the portal vein
Uncontrolled active bleeding
Platelet count lower than 10*10^9/L
Creatinine more than 170 mmol/L
Ongoing or received antithrombotic/thrombolytic treatment
Primary thrombophilia
Budd-Chiari syndrome
Pregnancy or breast-feeding period
Severe cardiopulmonary diseases
Severe systemic infection or sepsis
Inability to sign informed consent

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04173429). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.